BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21314729)

  • 1. Evaluation of cytoreductive efficacy of vincristine, cyclophosphamide, and Doxorubicin in dogs with lymphoma by measuring the number of neoplastic lymphoid cells with real-time polymerase chain reaction.
    Sato M; Yamazaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
    J Vet Intern Med; 2011; 25(2):285-91. PubMed ID: 21314729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol.
    Tomiyasu H; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
    J Vet Med Sci; 2010 Nov; 72(11):1391-7. PubMed ID: 20543531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in minimal residual disease in peripheral blood before clinical relapse in dogs with lymphoma that achieved complete remission after chemotherapy.
    Sato M; Yamazaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
    J Vet Intern Med; 2011; 25(2):292-6. PubMed ID: 21314721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of minimal residual disease (MRD) after multidrug chemotherapy and its correlation to outcome in dogs with lymphoma: a proof-of-concept pilot study.
    Yamazaki J; Takahashi M; Setoguchi A; Fujino Y; Ohno K; Tsujimoto H
    J Vet Intern Med; 2010; 24(4):897-903. PubMed ID: 20492493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
    Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
    J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
    Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
    Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic significance of minimal residual disease in the early phases of chemotherapy in dogs with high-grade B-cell lymphoma.
    Sato M; Yamzaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
    Vet J; 2013 Mar; 195(3):319-24. PubMed ID: 22909955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.
    Davies O; Szladovits B; Polton G; Garden OA; Leo C; Lara-Garcia A
    Vet Comp Oncol; 2018 Jun; 16(2):276-287. PubMed ID: 29271043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.
    Hosoya K; Kisseberth WC; Lord LK; Alvarez FJ; Lara-Garcia A; Kosarek CE; London CA; Couto CG
    J Vet Intern Med; 2007; 21(6):1355-63. PubMed ID: 18196747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of temporal association of relapse of canine multicentric lymphoma with components of the CHOP protocol: Is cyclophosphamide the weakest link?
    Wang SL; Lee JJ; Liao AT
    Vet J; 2016 Jul; 213():87-9. PubMed ID: 27240922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma.
    Moore AS; Cotter SM; Rand WM; Wood CA; Williams LE; London CA; Frimberger AE; L'Heureux DA
    J Vet Intern Med; 2001; 15(4):348-54. PubMed ID: 11467592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
    Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
    Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study.
    Mason SL; Grant IA; Elliott J; Cripps P; Blackwood L
    J Small Anim Pract; 2014 Aug; 55(8):391-8. PubMed ID: 24920169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma.
    Rebhun RB; Kent MS; Borrofka SA; Frazier S; Skorupski K; Rodriguez CO
    Vet Comp Oncol; 2011 Mar; 9(1):38-44. PubMed ID: 21303452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot clinical study of carmustine associated with a lipid nanoemulsion in combination with vincristine and prednisone for the treatment of canine lymphoma.
    Lucas SR; Maranhão RC; Guerra JL; Coelho BM; Barboza R; Pozzi DH
    Vet Comp Oncol; 2015 Sep; 13(3):184-93. PubMed ID: 23615221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
    Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
    J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
    Garrett LD; Thamm DH; Chun R; Dudley R; Vail DM
    J Vet Intern Med; 2002; 16(6):704-9. PubMed ID: 12465768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs.
    Rassnick KM; Moore AS; Collister KE; Northrup NC; Kristal O; Chretin JD; Bailey DB
    J Vet Intern Med; 2009; 23(2):317-22. PubMed ID: 19192147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma?
    Hahn KA; Richardson RC; Teclaw RF; Cline JM; Carlton WW; DeNicola DB; Bonney PL
    J Vet Intern Med; 1992; 6(1):3-10. PubMed ID: 1548624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
    Simon D; Moreno SN; Hirschberger J; Moritz A; Kohn B; Neumann S; Jurina K; Scharvogel S; Schwedes C; Reinacher M; Beyerbach M; Nolte I
    J Am Vet Med Assoc; 2008 Mar; 232(6):879-85. PubMed ID: 18341445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.